Related Experiment Videos

Pharmacokinetic study of mizoribine in child-onset glomerulonephritis

Yoshifusa Abe1, Takeshi Mikawa, Toshiya Fuke

  • 1Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan.

Pediatrics International : Official Journal of the Japan Pediatric Society
|March 6, 2009
PubMed
Abstract

Insights

This study details the pharmacokinetics of mizoribine (MZR) in children with glomerulonephritis. Findings provide key MZR parameters to guide effective treatment for pediatric kidney disease.

Area of Science:

  • Pediatric Nephrology
  • Clinical Pharmacology
  • Immunosuppressive Therapy

Background:

  • Mizoribine (MZR) is used for glomerulonephritis with few adverse effects.
  • Limited pharmacokinetic data exists for MZR, especially in pediatric populations.

Purpose of the Study:

  • To conduct a pharmacokinetic study of mizoribine in child-onset glomerulonephritis.
  • To establish key pharmacokinetic parameters for MZR in pediatric patients.

Main Methods:

  • Oral administration of MZR (60-300 mg/day) to nine pediatric patients.
  • Collection of blood and urine samples for concentration-time profiling.
  • Estimation of pharmacokinetic parameters using non-parametric analysis.

Main Results:

  • Key parameters determined: Tmax (2.94 h), Cmax (1.59 µg/mL), t1/2 (1.96 h), AUC0-inf (9.36 µg·h/mL), Vdss (2.03 L/kg).
  • Urinary excretion rate of MZR was 49.1%.
  • Dose ranged from 3.0-8.4 mg/kg/day.

Conclusions:

  • Estimated pharmacokinetic parameters are valuable for MZR treatment in child-onset glomerulonephritis.
  • Provides a foundation for optimizing MZR dosing in pediatric kidney disease.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...